This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Young, E. A. Articles by Akil, H. Search for Related Content PubMed PubMed Citation Articles by Young, E. A. Articles by Akil, H.

The Role of Mineralocorticoid Receptors in Hypothalamic-Pituitary-Adrenal Axis Regulation in Humans¹

Mental Health Research Institute and Department of Psychiatry, University of Michigan, Ann Arbor, Michigan 48109

Address all correspondence and requests for reprints to: Dr. Elizabeth A. Young, Mental Health Research Institute and Department of Psychiatry, 205 Zina Pitcher Place, University of Michigan, Ann Arbor, Michigan 48109. E-mail: eayoung{at}umich.edu

In rodents, two types of glucocorticoid receptors, the mineralocorticoid (MR; type I) and the glucocorticoid (type II) receptors, have been demonstrated to play a role in hypothalamic-pituitary-adrenal (HPA) axis regulation. Because MR shows a very high affinity for cortisol, it has been suggested that MR plays an important role in restraint of CRH and ACTH secretion during the nadir of the circadian rhythm. Although a number of studies have established the importance of MR in rodents, the functional role of MR in humans has not been determined. These studies evaluated whether spironolactone, an MR antagonist, had a detectable effect on HPA axis regulation in humans, and whether the effect was greatest during the evening, when plasma cortisol concentrations are in the MR range. Compared to the placebo day, after a single dose of spironolactone at either 0800 or 1600 h, there is a significant increase in plasma cortisol, which is preceded by a rise in ACTH and ß-endorphin. A significant effect of spironolactone on cortisol secretion was demonstrated with no differences between the morning and evening. Because the effect of spironolactone on cortisol was short lived, a second experiment was conducted using two doses of spironolactone, again sampling in the morning and evening. After two doses of spironolactone, plasma cortisol levels showed a significant and sustained spironolactone-induced elevation for the entire sampling period. However, neither plasma ß-endorphin nor ACTH was increased compared to levels on the placebo day. These data suggest that MR appear to play a clear role in HPA axis regulation during the time of the circadian peak as well as the trough. Furthermore, MR blockade may affect the sensitivity of the adrenal to ACTH.

This article has been cited by other articles:

				C. Mattsson, R. M. Reynolds, K. Simonyte, T. Olsson, and B. R. Walker Combined Receptor Antagonist Stimulation of the Hypothalamic-Pituitary-Adrenal Axis Test Identifies Impaired Negative Feedback Sensitivity to Cortisol in Obese Men J. Clin. Endocrinol. Metab., April 1, 2009; 94(4): 1347 - 1352. [Abstract] [Full Text] [PDF]

				H. C. Atkinson, S. A. Wood, E. S. Castrique, Y. M. Kershaw, C. C. R. Wiles, and S. L. Lightman Corticosteroids mediate fast feedback of the rat hypothalamic-pituitary-adrenal axis via the mineralocorticoid receptor Am J Physiol Endocrinol Metab, June 1, 2008; 294(6): E1011 - E1022. [Abstract] [Full Text] [PDF]

				D. Fraccarollo, P. Galuppo, S. Schraut, S. Kneitz, N. van Rooijen, G. Ertl, and J. Bauersachs Immediate Mineralocorticoid Receptor Blockade Improves Myocardial Infarct Healing by Modulation of the Inflammatory Response Hypertension, April 1, 2008; 51(4): 905 - 914. [Abstract] [Full Text] [PDF]

				A. Peters, M. Conrad, C. Hubold, U. Schweiger, B. Fischer, and H. L. Fehm The principle of homeostasis in the hypothalamus-pituitary-adrenal system: new insight from positive feedback Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2007; 293(1): R83 - R98. [Abstract] [Full Text] [PDF]

				A. M. Rozeboom, H. Akil, and A. F. Seasholtz Mineralocorticoid receptor overexpression in forebrain decreases anxiety-like behavior and alters the stress response in mice PNAS, March 13, 2007; 104(11): 4688 - 4693. [Abstract] [Full Text] [PDF]

				R. H. DeRijk, S. Wust, O. C. Meijer, M.-C. Zennaro, I. S. Federenko, D. H. Hellhammer, G. Giacchetti, E. Vreugdenhil, F. G. Zitman, and E. R. de Kloet A Common Polymorphism in the Mineralocorticoid Receptor Modulates Stress Responsiveness J. Clin. Endocrinol. Metab., December 1, 2006; 91(12): 5083 - 5089. [Abstract] [Full Text] [PDF]

				R. Giordano, M. Bo, M. Pellegrino, M. Vezzari, M. Baldi, A. Picu, M. Balbo, L. Bonelli, G. Migliaretti, E. Ghigo, et al. Hypothalamus-Pituitary-Adrenal Hyperactivity in Human Aging Is Partially Refractory to Stimulation by Mineralocorticoid Receptor Blockade J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5656 - 5662. [Abstract] [Full Text] [PDF]

				T. W. W. Pace and R. L. Spencer Disruption of mineralocorticoid receptor function increases corticosterone responding to a mild, but not moderate, psychological stressor Am J Physiol Endocrinol Metab, June 1, 2005; 288(6): E1082 - E1088. [Abstract] [Full Text] [PDF]

				P. Wellhoener, J. Born, H. L. Fehm, and C. Dodt Elevated Resting and Exercise-Induced Cortisol Levels after Mineralocorticoid Receptor Blockade with Canrenoate in Healthy Humans J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 5048 - 5052. [Abstract] [Full Text] [PDF]

				M. Guido, D. Romualdi, M. Giuliani, R. Suriano, L. Selvaggi, R. Apa, and A. Lanzone Drospirenone for the Treatment of Hirsute Women with Polycystic Ovary Syndrome: A Clinical, Endocrinological, Metabolic Pilot Study J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 2817 - 2823. [Abstract] [Full Text] [PDF]

				C. Otte, A. Yassouridis, H. Jahn, P. Maass, N. Stober, K. Wiedemann, and M. Kellner Mineralocorticoid Receptor-Mediated Inhibition of the Hypothalamic-Pituitary-Adrenal Axis in Aged Humans J. Gerontol. A Biol. Sci. Med. Sci., October 1, 2003; 58(10): B900 - 905. [Abstract] [Full Text] [PDF]

				C. Mattsson, M. Lai, J. Noble, E. McKinney, J. L. Yau, J. R. Seckl, and B. R. Walker Obese Zucker Rats Have Reduced Mineralocorticoid Receptor and 11{beta}-Hydroxysteroid Dehydrogenase Type 1 Expression in Hippocampus--Implications for Dysregulation of the Hypothalamic-Pituitary-Adrenal Axis in Obesity Endocrinology, July 1, 2003; 144(7): 2997 - 3003. [Abstract] [Full Text] [PDF]

				D. J. Clegg, S. C. Benoit, E. L. Air, A. Jackman, P. Tso, D. D'Alessio, S. C. Woods, and R. J. Seeley Increased Dietary Fat Attenuates the Anorexic Effects of Intracerebroventricular Injections of MTII Endocrinology, July 1, 2003; 144(7): 2941 - 2946. [Abstract] [Full Text] [PDF]

				E. A. Young, J. F. Lopez, V. Murphy-Weinberg, S. J. Watson, and H. Akil Mineralocorticoid Receptor Function in Major Depression Arch Gen Psychiatry, January 1, 2003; 60(1): 24 - 28. [Abstract] [Full Text] [PDF]

				M. Kellner, D. G. Baker, A. Yassouridis, S. Bettinger, C. Otte, D. Naber, and K. Wiedemann Mineralocorticoid Receptor Function in Patients With Posttraumatic Stress Disorder Am J Psychiatry, November 1, 2002; 159(11): 1938 - 1940. [Abstract] [Full Text] [PDF]

				S. Grottoli, R. Giordano, B. Maccagno, M. Pellegrino, E. Ghigo, and E. Arvat The Stimulatory Effect of Canrenoate, a Mineralocorticoid Antagonist, on the Activity of the Hypothalamus-Pituitary-Adrenal Axis Is Abolished by Alprazolam, a Benzodiazepine, in Humans J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4616 - 4620. [Abstract] [Full Text] [PDF]

				E. Arvat, B. Maccagno, R. Giordano, M. Pellegrino, F. Broglio, L. Gianotti, M. Maccario, F. Camanni, and E. Ghigo Mineralocorticoid Receptor Blockade by Canrenoate Increases Both Spontaneous and Stimulated Adrenal Function in Humans J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 3176 - 3181. [Abstract] [Full Text] [PDF]